# A Study Evaluating IV Oncaspar® and IV Gemzar® in the Treatment of Solid Tumors and Lymphoma

> **NCT00363610** · PHASE1 · TERMINATED · sponsor: **Enzon Pharmaceuticals, Inc.** · enrollment: 19 (actual)

## Conditions studied

- Tumors
- Lymphoma

## Interventions

- **DRUG:** Oncaspar & Gemzar; advanced and/or solid tumors and lymphoma

## Key facts

- **NCT ID:** NCT00363610
- **Lead sponsor:** Enzon Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-07
- **Primary completion:** 2007-11
- **Final completion:** 2008-06
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** No recommended Phase II dose was determined.
- **Last updated:** 2008-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00363610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00363610, "A Study Evaluating IV Oncaspar® and IV Gemzar® in the Treatment of Solid Tumors and Lymphoma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00363610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*